ReviewFrontiers in immunology2021
Schistosomes in the Lung: Immunobiology and Opportunity.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Cellular heterogeneity of hepatic granuloma formation and evolution in murine schistosomiasis japonica.Nature communications · 2026Article
- Pulmonary Immune Cell Landscape Altered by Exposure to HIV,International journal of molecular sciences · 2026Article
- Nonlinear Imaging Allows to Characterize Granulomas and Fibrosis in Mice Tissue From Experimental Schistosomiasis.Journal of biophotonics · 2026Article
- An update on schistosomicide and tumoricide in the future: arachidonic acid.Lipids in health and disease · 2025Review
- Epidemiological, clinical and immunological features of Schistosoma spp., Stronglyoides stercoralis and Taenia spp. infections in Ghanaian HIV patients.European journal of microbiology & immunology · 2025Article
- Survival of patients with hepatopulmonary syndrome related to cirrhotic and non-cirrhotic (schistosomiasis) portal hypertension.World journal of hepatology · 2025Article
- Glucocorticoid receptor inhibits Th2 immune responses by down-regulating Pparg and Gata3 in schistosomiasis.Frontiers in immunology · 2025Article
- Malaria, urogenital schistosomiasis and co-infection and nutritional status of school children in Ondo state.PloS one · 2025Article
- Large Mediastinal Mass as a Rare Presentation of Schistosomiasis.International journal of surgical pathology · 2024Article
- A Recent Advance in the Diagnosis, Treatment, and Vaccine Development for Human Schistosomiasis.Tropical medicine and infectious disease · 2024Review
- Review
- Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics.PLoS neglected tropical diseases · 2024Article
- The unusual location of primary hydatid cyst: A case series study.Open medicine (Warsaw, Poland) · 2024Article
- Katayama syndrome disguised as eosinophilic asthma with acute systemic symptoms and pulmonary nodules.Respiratory medicine case reports · 2024Article
- Individually or as a Team-The Immunological Milieu in the Lung Caused by Migrating Single-Sex or Mixed-Sex Larvae ofPathogens (Basel, Switzerland) · 2023Article
- Single-cell RNA sequencing reveals a peripheral landscape of immune cells in Schistosomiasis japonica.Parasites & vectors · 2023Article
- Targeting helminths: The expanding world of type 2 immune effector mechanisms.The Journal of experimental medicine · 2023Review
- Clinicopathological characteristics and its association with digestive system tumors of 1111 patients with Schistosomiasis japonica.Scientific reports · 2023Article
- Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis.Nature communications · 2023Article
- Immunological mechanisms involved in macrophage activation and polarization in schistosomiasis.Parasitology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Schistosome infection is a major cause of global morbidity, particularly in sub-Saharan Africa. However, there is no effective vaccine for this major neglected tropical disease, and re-infection routinely occurs after chemotherapeutic treatment. Following invasion through the skin, larval schistosomula enter the circulatory system and migrate through the lung before maturing to adulthood in the mesenteric or urogenital vasculature. Eggs released from adult worms can become trapped in various tissues, with resultant inflammatory responses leading to hepato-splenic, intestinal, or urogenital disease - processes that have been extensively studied in recent years. In contrast, although lung pathology can occur in both the acute and chronic phases of schistosomiasis, the mechanisms underlying pulmonary disease are particularly poorly understood. In chronic infection, egg-mediated fibrosis and vascular destruction can lead to the formation of portosystemic shunts through which eggs can embolise to the lungs, where they can trigger granulomatous disease. Acute schistosomiasis, or Katayama syndrome, which is primarily evident in non-endemic individuals, occurs during pulmonary larval migration, maturation, and initial egg-production, often involving fever and a cough with an accompanying immune cell infiltrate into the lung. Importantly, lung migrating larvae are not just a cause of inflammation and pathology but are a key target for future vaccine design. However, vaccine efforts are hindered by a limited understanding of what constitutes a protective immune response to larvae. In this review, we explore the current understanding of pulmonary immune responses and inflammatory pathology in schistosomiasis, highlighting important unanswered questions and areas for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.